Genentech, MedImmune Settle Synagis Patent Spat
Biotechnology giant Genentech Inc. has dropped its patent dispute over MedImmune Inc.'s blockbuster drug Synagis, but its battle to uphold the validity of the patent at the center of the litigation...To view the full article, register now.
Already a subscriber? Click here to view full article